In support of this hypothesis, a recent study that used the combination of MDM2i and CDK4/6i in patient derived models of melanoma with insensitivity or resistance to CDK4/6i (70), did report a synergistic response and identified increased cell cycle arrest and gene expression changes consistent with senescence in combination treated samples. This evidence concerns the gene CDK4 and melanoma.